Loading...

Follow Renal and Urology News | Prostate Cancer on Feedspot

Continue with Google
Continue with Facebook
or

Valid

New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.
Read Full Article

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview